View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsMaxrets Ventures 過去の業績過去 基準チェック /06Maxrets Ventures は平均年間 14.5% の収益成長を遂げていますが、Pharmaceuticals 業界では年間 収益成長率 となっています。3.4% です。主要情報14.49%収益成長率14.49%EPS成長率Pharmaceuticals 業界の成長14.12%収益成長率n/a株主資本利益率-2,515.79%ネット・マージンn/a前回の決算情報31 Oct 2023最近の業績更新お知らせ • Jul 31MaxRets Ventures plc to Report First Half, 2023 Results on Jul 31, 2023MaxRets Ventures plc announced that they will report first half, 2023 results on Jul 31, 2023すべての更新を表示Recent updatesNew Risk • Nov 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended October 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (UK£332.8k market cap, or US$417.1k). Minor Risk Latest financial reports are more than 6 months old (reported October 2023 fiscal period end).New Risk • Oct 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (UK£591.7k market cap, or US$785.8k). Minor Risk Share price has been volatile over the past 3 months (8.7% average weekly change).New Risk • May 01New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (21% average weekly change). Market cap is less than US$10m (UK£961.5k market cap, or US$1.20m).New Risk • Nov 20New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended October 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (UK£2.96m market cap, or US$3.69m). Minor Risk Latest financial reports are more than 6 months old (reported October 2022 fiscal period end).お知らせ • Jul 31MaxRets Ventures plc to Report First Half, 2023 Results on Jul 31, 2023MaxRets Ventures plc announced that they will report first half, 2023 results on Jul 31, 2023Board Change • Jun 06Less than half of directors are independentThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Non-Executive Director Monica Formenti is the most experienced director on the board, commencing their role in 2021. Independent Non-Executive Director Martin Walton was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.お知らせ • May 31MaxRets Ventures plc, Annual General Meeting, Jun 22, 2023MaxRets Ventures plc, Annual General Meeting, Jun 22, 2023, at 14:00 Coordinated Universal Time. Location: 50, Sloane Avenue, London, SW3 3DD London United KingdomBoard Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Jun 14Greencare Capital plc, Annual General Meeting, Jul 07, 2022Greencare Capital plc, Annual General Meeting, Jul 07, 2022, at 09:00 Coordinated Universal Time. Location: 50 Sloane Avenue, London, SW3 3DD London United KingdomBoard Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Guy Winterflood was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.収支内訳Maxrets Ventures の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OFEX:MAX 収益、費用、利益 ( )GBP Millions日付収益収益G+A経費研究開発費31 Oct 23000031 Oct 220-11031 Jul 220-11030 Apr 220-11031 Jan 22000031 Oct 21000030 Apr 21000031 Jan 210000質の高い収益: MAXは現在利益が出ていません。利益率の向上: MAXは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: MAXの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: MAXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: MAXは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( 33.7% ) と比較することは困難です。株主資本利益率高いROE: MAXは現在利益が出ていないため、自己資本利益率 ( -2515.79% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/03/19 19:12終値2025/03/17 00:00収益2023/10/31年間収益2023/10/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Maxrets Ventures Plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jul 31MaxRets Ventures plc to Report First Half, 2023 Results on Jul 31, 2023MaxRets Ventures plc announced that they will report first half, 2023 results on Jul 31, 2023
New Risk • Nov 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended October 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (UK£332.8k market cap, or US$417.1k). Minor Risk Latest financial reports are more than 6 months old (reported October 2023 fiscal period end).
New Risk • Oct 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (UK£591.7k market cap, or US$785.8k). Minor Risk Share price has been volatile over the past 3 months (8.7% average weekly change).
New Risk • May 01New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (21% average weekly change). Market cap is less than US$10m (UK£961.5k market cap, or US$1.20m).
New Risk • Nov 20New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended October 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (UK£2.96m market cap, or US$3.69m). Minor Risk Latest financial reports are more than 6 months old (reported October 2022 fiscal period end).
お知らせ • Jul 31MaxRets Ventures plc to Report First Half, 2023 Results on Jul 31, 2023MaxRets Ventures plc announced that they will report first half, 2023 results on Jul 31, 2023
Board Change • Jun 06Less than half of directors are independentThere are 3 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Non-Executive Director Monica Formenti is the most experienced director on the board, commencing their role in 2021. Independent Non-Executive Director Martin Walton was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
お知らせ • May 31MaxRets Ventures plc, Annual General Meeting, Jun 22, 2023MaxRets Ventures plc, Annual General Meeting, Jun 22, 2023, at 14:00 Coordinated Universal Time. Location: 50, Sloane Avenue, London, SW3 3DD London United Kingdom
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Jun 14Greencare Capital plc, Annual General Meeting, Jul 07, 2022Greencare Capital plc, Annual General Meeting, Jul 07, 2022, at 09:00 Coordinated Universal Time. Location: 50 Sloane Avenue, London, SW3 3DD London United Kingdom
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Non-Executive Director Guy Winterflood was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.